Drug Profile
SNX 5422
Alternative Names: 113; PF-04929113; PF-113; PF-4929113; SNX-5422Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Serenex
- Developer Esanex; Serenex
- Class Amides; Antineoplastics; Indazoles; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer
- Discontinued Chronic lymphocytic leukaemia; Haematological malignancies; Lung cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO)
- 28 Dec 2022 Discontinued - Phase-I for Haematological malignancies (Refractory metastatic disease) in USA (PO)
- 28 Dec 2022 Discontinued - Phase-I for Lung cancer (Late-stage disease, Second-line therapy or greater) in USA (PO)